药驾(Driving Under The Influence of Drugs,DUID)中的女性,由于受用药特殊性及女性药代动力学与药效动力学特殊性的影响,具有与男性药驾不同的特点。近年来,女性药驾引发交通事故的现象逐渐引起国内外研究者的关注。为促进相关研究,...药驾(Driving Under The Influence of Drugs,DUID)中的女性,由于受用药特殊性及女性药代动力学与药效动力学特殊性的影响,具有与男性药驾不同的特点。近年来,女性药驾引发交通事故的现象逐渐引起国内外研究者的关注。为促进相关研究,通过综合分析国内外文献,从三方面介绍了女性驾驶能力受药物影响的国内外研究成果,分析了该类研究目前存在的不足,对进一步的研究提出了建议,并对该类研究的发展趋势进行了初步预测。展开更多
Esophageal squamous cell carcinoma continues to heavily burden clinicians worldwide. Researchers have discovered the genomic landscape of esophageal squamous cell carcinoma, which holds promise for an era of personali...Esophageal squamous cell carcinoma continues to heavily burden clinicians worldwide. Researchers have discovered the genomic landscape of esophageal squamous cell carcinoma, which holds promise for an era of personalized oncology care. One of the most pressing problems facing this issue is to improve the understanding of the newly available genomic data, and identify the driver-gene mutations, pathways, and networks. The emergence of a legion of novel targeted agents has generated much hope and hype regarding more potent treatment regimens, but the accuracy of drug selection is still arguable. Other problems, such as cancer heterogeneity, drug resistance, exceptional responders, and side effects, have to be surmounted. Evolving topics in personalized oncology, such as interpretation of genomics data, issues in targeted therapy, research approaches for targeted therapy, and future perspectives, will be discussed in this editorial.展开更多
文摘药驾(Driving Under The Influence of Drugs,DUID)中的女性,由于受用药特殊性及女性药代动力学与药效动力学特殊性的影响,具有与男性药驾不同的特点。近年来,女性药驾引发交通事故的现象逐渐引起国内外研究者的关注。为促进相关研究,通过综合分析国内外文献,从三方面介绍了女性驾驶能力受药物影响的国内外研究成果,分析了该类研究目前存在的不足,对进一步的研究提出了建议,并对该类研究的发展趋势进行了初步预测。
基金Supported by Grants from Beijing Academic Leaders Program,NO.2009-2-17Beijing Natural Science Foundation,No.7102029+5 种基金Capital Medical Developed Research Fund,No.2007-1023New Scholar Star Program of Ministry of EducationNational Basic Research Program of China,No.2011CB504300Specialized Research Fund for the Doctoral Program of Higher Education,No.20130001110108National Natural Science Foundation for Distinguished Young Scholars,No.81301748Science Fund for Creative Research Groups of the National Natural Science Foundation of China,No.IRT13003 and No.NIH/NCI U54 CA156735
文摘Esophageal squamous cell carcinoma continues to heavily burden clinicians worldwide. Researchers have discovered the genomic landscape of esophageal squamous cell carcinoma, which holds promise for an era of personalized oncology care. One of the most pressing problems facing this issue is to improve the understanding of the newly available genomic data, and identify the driver-gene mutations, pathways, and networks. The emergence of a legion of novel targeted agents has generated much hope and hype regarding more potent treatment regimens, but the accuracy of drug selection is still arguable. Other problems, such as cancer heterogeneity, drug resistance, exceptional responders, and side effects, have to be surmounted. Evolving topics in personalized oncology, such as interpretation of genomics data, issues in targeted therapy, research approaches for targeted therapy, and future perspectives, will be discussed in this editorial.
